Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Inclusion Criteria:

• Written Informed Consent Form

• Females that are not pregnant or breastfeeding with following condition: not a womanof childbearing potential or woman of childbearing potential using a highlyeffective contraception method

• Physician-diagnosis of asthma and documented evidence of airway reversibility duringprior 24 months or during screening

• Airflow limitation as indicated by pre-BD FEV1 value of ≥ 30% and ≤ 90%, predictedat two visits at Screening

• Low, medium-, or high-dose ICS and ≥1 maintenance asthma controller medication (LABA/LTRA/LAMA/chromones/theophylline)

Exclusion Criteria:

• Participants with a known, pre-existing, clinically important lung condition otherthan asthma

• Active tuberculosis or treatment required for tuberculosis within 12 months

• Current or former smokers ≥10 pack years

• History of cancer

• Receipt of any marketed biologic agent within 4 months or 5 half-lives prior toscreening; receipt of immunoglobulin or blood products within 30 days prior toscreening or during the Screening Run-in period; receipt of any live or attenuatedvaccines within 15 days prior to screening

• Helminth infection within 24 weeks prior to screening

• Use of immunosuppressive medication within 3 months prior to Screening Visit orduring the Screening Run-in period

• Participants who are pregnant, lactating or breastfeeding